Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 38M | 33M | 44M | 95M | 188M |
| Gross Profit | 47K | -1M | 9M | 28M | 95M |
| Operating Income | -20M | -21M | -11M | -853K | 73M |
| EBITDA | -12M | 4M | -1M | 10M | 76M |
| Net Income | -13M | -12M | -7M | 5M | 56M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.6999
+1.43% today
1Y Change
+6.15%
Window
Jun 23, 2025 → Jun 8, 2026
Coverage: 241 bars · Jun 23, 2025 → Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Retractable Technologies, Inc. (RVP) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $0.70 and up 6.2% across the available one-year price window (Jun 23, 2025 → Jun 8, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of -7.5%, a dividend yield of 0.0%. What stands out right now is revenue +15.8%, EPS -7.5%, free cash flow +41.5% with operating margin -52.8% and ROIC -15.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RVP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVP Max Drawdown
-41.51%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$188.4M
+98.7% YoY
FY Net Income
$56.1M
+1003.9% YoY
Free Cash Flow
-$25.6M
-41180.2% YoY
Revenue Growth
+15.8%
EPS Growth
-7.5%
Gross Margin
0.1%
Net Margin
-32.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 38M | 33M | 44M | 95M | 188M |
| Gross Profit | 47K | -1M | 9M | 28M | 95M |
| Operating Income | -20M | -21M | -11M | -853K | 73M |
| EBITDA | -12M | 4M | -1M | 10M | 76M |
| Net Income | -13M | -12M | -7M | 5M | 56M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 4M | 13M | 20M | 29M |
| Total Assets | 143M | 161M | 180M | 211M | 213M |
| Total Liabilities | 68M | 74M | 80M | 104M | 114M |
| Shareholder Equity | 74M | 87M | 99M | 107M | 99M |
| Total Debt | 365K | 1M | 2M | 3M | 4M |
| Net Debt | -2M | -3M | -11M | -17M | -25M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
33M
+95.6% YoY
Capital Expenditures
58M
-246.8% YoY
Free Cash Flow
26M
-41180.2% YoY
Key ratios
Gross Margin
0.1%
Operating Margin
-52.8%
Net Margin
-32.8%
ROE
-16.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.